a Objective: The impact of short-term analytical treatment interruptions (ATI) on the levels of cellular HIV and of residual activation after subsequent antiretroviral therapy (ART)-mediated plasma HIV viral load re-suppression remains under active investigation.
Introduction
HIV cure-directed studies aim to permanently cease HIV replication after cessation of antiretroviral therapy (ART). The ability to block viral HIV replication after interruption of ART requires a strategy that can eradicate or control persistent measures of HIV before or during ART interruption. HIV cure-directed clinical strategies have tested therapy intensification [1] [2] [3] [4] [5] [6] [7] , purging of HIV-1 from the latent reservoir in the presence of ART (e.g. using T-cell activating cytokines [8] [9] [10] [11] , histone deacetylase inhibitors [12] [13] [14] , etc.), cytokine immunotherapy [15] , or gene therapy [16, 17] . A limitation of all current HIV-cure-directed clinical research is the inability to accurately predict whether changes detected in persistent HIV or immune modulation while on suppressive ART are directly associated with control of HIV absent ART. Therefore, ART interruption and a closely monitored period of observation for the return of viremia is commonly included, as an 'analytical' treatment interruption (ATI) period. The role of an ATI step in determining the ultimate success of a cure-directed strategy is often counter-balanced by the concern for the potential risk of reversing the gains of long-term ART suppression upon return of viral replication. Prolonged ATI can have deleterious consequences [18] . Therefore, there is concern that the rise of plasma HIV viral load (RNA) during an ATI, however, limited will result in a rise in residual immune activation and a higher amount of persistent cellular HIV after subsequent ART-mediated plasma HIV RNA re-suppression.
We previously reported the results of a longitudinal randomized, open-label, single-center study investigating the immune, viral, and safety outcomes of ATIs in patients with chronically suppressed HIV-1 infection as compared to equal follow-up of patients on continuous ART and including a final therapy interruption in both arms [19] . In the current study, we used activation data and cryopreserved peripheral blood mononuclear cells (PBMC) from the above-mentioned parent study to investigate whether an ATI-mediated viremic episode, during which cellular HIV RNA and total DNA levels and immune activation rose, would irreversibly change the pre-ATI levels of cellular HIV RNA and total DNA load when measured following plasma HIV re-suppression with resumption of ART.
Materials and methods

Study participants
Cryopreserved PBMC samples for the current study were derived from peripheral blood collected from 23 ARTsuppressed, chronically HIV-1 infected patients participating in a treatment interruption study (parent cohort of 42 patients).
Patient demographics and parent study were previously described [19, 20] . Briefly, in the parent study, patients were randomized in a continuous therapy/single interruption arm undergoing 40 weeks on continuous ART (Phase I) followed by an open-ended ATI (Phase II), and a repeated interruptions arm undergoing three sequential interruptions [Phase I: ATI number 1 (2 weeks), ATI number 2 (4 weeks), ATI number 3 (6 weeks) ] followed by an open-ended ATI (Phase II). Recruitment characteristics in the parent study were as follows: patients at least 18 years old, receiving ART (at least three drugs), with more than 400 CD4 þ T cells/ml of blood with a history of nadir CD4 þ T-cell count of at least 100 cells/ml, and plasma HIV-1 RNA of less than 50 copies/ml at the time of ART interruption. All participants of the parent study had a history of ARTmediated suppression of less than 500 copies/ml for more than 6 months. As previously described, in the parent study criteria for ART re-initiation in open-ended ATI were a viral load greater than 500 000 copies/ml, or a viral load greater than 30 000 copies/ml for three consecutive time points, or a drop in CD4 þ T-cell count more than 45% [19] .
In the current study, PBMC were evaluated at the initiation of a monitored ATI while on ART (baseline, time point 1), during ATI-associated HIV viremia (time point 2) and following re-suppression of HIV RNA after the resumption of ART (time points 3 and 4). Selection of the monitored ATI used in the current study was based on the following criteria: presence of a viremic episode (i.e. plasma HIV-RNA >50 copies/ml), and available samples for all time points studied. The first ATI that met these criteria was used for analysis. Informed consent for the parent study was obtained according to the Human Experimentation Guidelines of the US Department of Health and Human Services and of the authors' institutions. The study protocol was approved by the Institutional Review Boards of the Wistar Institute and Philadelphia FIGHT.
Assessment of T-cell activation phenotypes by flow cytometry T-cell activation data collected during the parent study (parent cohort of 42 patients) were available for statistical analysis in the current study. In the parent study, assessment of T-cell activation [frequency and mean fluorescence intensity (MFI) of CD38, HLA-DR, CD28, CD95 and TNFRII expression on CD3
T cells] was performed using whole blood flow cytometry at the time of blood collection as previously described [21] [22] [23] by using the following directly conjugated anticell surface antigen antibodies: CD3-phycoerythrin (PE), CD38-PE, CD28-fluorescein isothiocyanate (FITC), CD4-allophycocyanin (APC), CD8-APC, isotypes: mouse IgG1-PE, mouse IgG2a-PE, mouse IgG1-FITC, mouse IgG2a-FITC, mouse IgG2b-APC, mouse IgG2a-TriColor (TC) (Pharmingen, San Diego, California, USA); CD95-FITC, CD4-FITC, HLA-DR-APC, CD4-TC, CD8-TC, isotypes: mouse IgG1-APC (CalTag, Burlingame, California, USA); and tumor necrosis factor II (TNFRII)-PE (R&D Systems, Minneapolis, Minnesota, USA).
Briefly, 100 ml of whole blood were first incubated for 10 min at room temperature (RT) with 10 ml of 10% mouse serum (Sigma-Aldrich, St. Louis, Missouri, USA), and then stained for 20 min at RT with the appropriate monoclonal antibody combinations. The cells were then lysed for 10 min at RT with 3 ml of FACS Lysis solution [Becton Dickinson (BD) Biosciences, San Diego, California, USA] and centrifuged for 5 min at 1200 rpm. Cells were subsequently washed twice with 3 ml of FACS washing buffer (1Â PBS, 2.5% heat inactivated FBS, 0.1% BSA, 0.02% NaN 3 ) at 1500 rpm, and re-suspended in 200 ml of FACS washing buffer. Samples were analyzed on a BD FACScalibur flow cytometer using the CellQuest software package for acquisition and analysis. Live cell gates were set manually during acquisition of 10 000 events for each staining. Detection thresholds were set according to isotypematched negative controls. Results were expressed as MFI and percentage positive.
Assessment of cellular HIV DNA, and 2-long terminal repeat circular HIV DNA DNA was extracted in the current study from cryopreserved PBMC (5-15 Â 10 6 cells/vial) for each time point using the AllPrep DNA/RNA minikit (Qiagen, Valencia, California, USA). Extracted DNA was then used to quantify cellular HIV DNA [total HIV DNA (polymerase, pol) and the long terminal repeat (2-LTR) junction] by droplet digital PCR (ddPCR) as previously described [24] [25] [26] . Briefly, 1000 ng of DNA per replicate were digested with BSAJ1 enzyme (New England BioLabs, Ipswich, Massachusetts, USA) before ddPCR quantification. Total HIV DNA ( pol) and 2-LTR PCRs were performed with a duplex assay using HEX ( pol) and FAM (2-LTR) probes, respectively, with the following cycling conditions: 10 min of initial enzyme activation at 95 8C, 40 cycles consisting of a 30-s denaturation at 94 8C followed by a 60 8C extension for 60 s, and a final inactivation of 10 min at 98 8C. The host cell RNase P/MRP 30-kDa-subunit gene (RPP30) was used as cellular normalizer, as it appears in 2 copies/cell. The digested DNA was diluted 10-fold, and 100 ng of the digested DNA/replicate were used for quantification of RPP30 by ddPCR (probe HEX) and cycled with the same parameters as for the pol, 2-LTR duplex. Copy numbers were calculated as the mean of replicate PCR measurements and normalized to 1 Â 10 6 PBMC and 1 Â 10 6 CD4 þ T cells as determined by RPP30 (total cell count) and flow cytometry (CD4 þ T cell %) [26] .
Assessment of cellular HIV RNA Cellular HIV RNA was extracted in the current study from cryo-preserved PBMC (5-15 Â 10 6 cells/vial) for each time point using the AllPrep DNA/RNA minikit (Qiagen) according the manufacturer's protocol. DNA contamination was avoided by addition of a DNase (RNase-free DNase Set; Qiagen) step to the protocol. Extracted RNA (500 ng) was then reverse transcribed into 20 ml of cDNA (iScript Advanced cDNA synthesis kit; Bio-Rad, Hercules, California, USA) according to the manufacturer's protocol, and the cDNA product (8 ml; approximately 300 ng) was added to the ddPCR mixture. PCRs for assessment of unspliced HIV RNA (usRNA; gag) and multiply spliced HIV RNA (msRNA; tat/rev) were performed as a duplex with HEX (unspliced gag) and FAM (multiply spliced tat/rev) probes, respectively, using primers and probes as previously described [25, 26] . Levels of all fully elongated and correctly processed HIV mRNA molecules (referred to as polyA) were also measured as previously described [26] [27] [28] , with the following cycling conditions for this PCR: 10 min at 95 8C, 60 cycles consisting of a 30-s denaturation at 94 8C followed by a 58 8C extension for 60 s, and a final 10 min at 98 8C. Copy numbers were calculated as the means of replicate PCR measurements and normalized to total RNA (1000 ng of total RNA) as determined by A260/A280 absorbance ratio using a NanoDrop 2000 spectrophotometer (Thermo Scientific, Waltham, Massachusetts, USA) [29] .
Statistical analysis
Clinical markers (i.e. plasma HIV-1 RNA, CD4
þ T cells/ml, CD4%) and T-cell activation data collected at the time of the parent study using whole blood, as well as cellular DNA and RNA data collected in the current study using cryopreserved PBMC from the parent study were used for statistical analysis. Data are presented as medians with 25th and 75th quartiles. For analysis and graphing purposes, plasma HIV RNA below 50 copies/ml was considered as equal to 50 copies/ml (threshold of detection). Differences between time points were assessed by Wilcoxon signed-rank test based on data distribution. Adjusted P values that were less than 0.1 are reported, based on the approach of Benjamini and Yekutieli (BY). Primary analysis focused on the comparison between baseline (time point 1) and post ATI (time points 3 and 4) levels of study variables. Correlations between T-cell activation and viral measures were assessed using Spearman's rank tests. Correlations were considered meaningful for Rho values above 0.3 with P values lower than 0.05. Analyses were performed using R version 2.5.1 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria), or JMP Pro 11 (SAS Institute, Cary, North Carolina, USA).
Results
Study patients and analytical treatment interruption duration A total of 23 ART-suppressed chronically HIV-1-infected patients were studied. Study patient characteristics are shown in Table 1 . Ten of 23 patients were in the continuous therapy/single interruption arm of the parent study and the remaining 13 patients were in the repeated interruption arm. No difference was found at baseline values of all study variables between patients from the continuous therapy/single interruption arm and patients from the repeated interruptions arm.
Clinical markers and T-cell activation data collected in the parent study as well as cellular DNA and RNA measured in the current study in cryopreserved PBMC from the parent study were evaluated at baseline on ART (time point 1), during a monitored ATI (time point 2) of a median duration of 4 weeks (IQR ¼ 4-9), and after plasma re-suppression of HIV RNA with resumption of ART (time point 3: median time on ART ¼ 13 weeks, IQR ¼ 12-18). The median peak plasma HIV RNA during ATI was 72900 copies/ml (IQR ¼ 32 558-127 193), whereas the HIV RNA at all time points on ART was less than 50 copies/ml. Ten of 23 patients had samples available for measurement of cellular DNA for an additional time point on ART (time point 4: median time after time point 3 ¼ 3 weeks, IQR ¼ 2-4).
Antiretroviral therapy-associated changes in plasma HIV viral load and T-cell activation return to pre-treatment interruption levels after antiretroviral therapy re-initiation We first assessed the impact of ATI and subsequent resumption of ARTon clinical markers (i.e. plasma HIV-1 RNA, CD4 þ T cells/ml, CD4%) and markers of T-cell activation using data collected in the parent study for the time points of the current study. Results are summarized in Fig. 1 , and Supplementary Table 1 , http://links.lww.com/QAD/B304. As expected, ATI resulted in a rise in plasma HIV RNA and a decrease in CD4 þ T cells/ml (P ¼ 0.0001), and CD4% (P ¼ 0.0004). 
þ HLA-DR þ T cells % at baseline of ATI while on ART (time point 1), during ATI (time point 2), and following ART-mediated HIV RNA re-suppression (time points 3 and 4). Data are shown per patient during follow-up with inter-quartile box plots with median and outliers, and significant P values. Different symbols/colors were used per patient as indicated in the side of the figure. ART, antiretroviral therapy; ATI, analytical treatment interruption.
Markers of activation (e.g. HLA-DR and CD38 coexpression and MFI of CD38 on T cells have been associated with disease progression [30] [31] [32] . As a result, changes in these markers were evaluated in this study along with other markers of T-cell activation. An increase from baseline in markers of Tcell activation (e.g. CD8
þ HLA-DR þ T cells: P ¼ 0.004) were noted during ATI-mediated viremia. The resumption of ART resulted in re-suppression of plasma HIV RNA and restored CD4 þ T cells/ml levels and frequencies of activated T cells to pre-ATI levels. No change was observed for CD4 þ CD38 þ % at any time point. Return to pre-ATI levels were further re-confirmed by a later time point on ART in 10 patients (time point 4).
Increases in cellular HIV RNA and DNA during analytical treatment interruption return to pre-analytical treatment interruption levels after re-initiation of antiretroviral therapy We assessed the effect of ATI and ART resumption on cellular HIV levels. First, ATI-mediated viremia (time point 2) resulted in an increase from baseline in cellular HIV DNA ( pol: P < 0.0001) and RNA [tat/rev: P < 0.0001; gag: P ¼ 0.0004; poly(A): P < 0.0001] levels. Second, as observed with T-cell activation changes, subsequent resumption of ART and plasma HIV RNA re-suppression (time points 3 and 4) returned levels of cellular HIV DNA ( pol) and RNA [tat/rev, gag, poly(A)] to pre-ATI levels (Fig. 2 , Supplementary Table 2 , http://links.lww.com/QAD/B304). Positive association between pre-analytical treatment interruption levels of T-cell activation and cellular HIV levels during analytical treatment interruption We also assessed the association between markers of T-cell activation and cellular HIV measures during follow-up. Although no significant association was observed following adjustments for multiple testing, unadjusted data showed an association between T-cell activation and HIV measures. First, pre-ATI levels (time point 1) of activated CD4 þ T cells (i.e. MFI of CD38 on CD4
þ HLA-DR þ T cells) were positively associated with cellular HIV DNA during ATI (time point 2, pol: P ¼ 0.03, Rho ¼ 0.44) and after ART-mediated plasma HIV RNA re-suppression (time point 3, P ¼ 0.03, Rho ¼ 0.47) (Fig. 3) . Interestingly, no association was observed between pre-ATI levels (time point 1) of T-cell activation and plasma HIV RNA during ATI (time point 2). Second, as expected, positive associations between T-cell activation and cellular HIV measures during ATI were detected [e.g. MFI of CD38 on CD8
þ HLA-DR þ T cells and tat/rev (P ¼ 0.01, Rho ¼ 0.52), gag (P ¼ 0.009, Rho ¼ 0.54), and poly(A) (P ¼ 0.009, Rho ¼ 0.54) respectively, Fig. 3 ].
Discussion
In this study, we assessed the impact of analytical treatment interruption on cellular HIV DNA and RNA levels and on residual activation before ATI and after ART re-initiation. We found no evidence that a monitored period of therapy interruption with associated viremia altered the levels of plasma and cellular HIV measures after resuming ART and achieving re-suppression.
Although proviral HIV DNA has been used as a general measure of cellular reservoir size, other measures such as 2-LTR circles and cellular RNA provide additional information about viral dynamics and presence of transcriptionally active cells [24] . Cellular HIV-1 DNA levels can represent an important virological correlate of the natural history of the disease as they are correlated with the extent of immunosuppression in naive patients [33, 34] , and can be informative on suppressive outcomes after ART treatment [35] . Therefore, a lack of change from pre-ATI levels of HIV DNA after re-suppression with ART as well as the lack of difference on HIV DNA baseline levels between patients with a history of multiple ATIs (i.e. repeated interruptions arm) and patients with no history of ATIs (i.e. continuous therapy/single interruption arm) provides re-assurance that monitored viremic episodes are unlikely to significantly reverse the benefits of ART or result in a larger latent reservoir after ATI in participants who initiated ART during chronic infection.
Our data in 23 patients confirm and extend previous studies [33, 36, 37] in smaller number of patients also showing a similar increase of cellular HIV DNA and RNA measures after viremia and therapy interruption, followed by a decline after resumption of therapy. Furthermore, it is important to note that our data are derived from a majority of short-term ATIs (most <6 weeks) in contrast to open-ended therapy interruptions, which may allow for months of viremia and a different outcome after restarting ART [18] . Moreover, our study now shows that the assessment of the different cellular viral RNAs produced in HIV-infected cells [msRNA (tat/rev), usRNA (gag), and poly(A) tailed transcripts] informs whether stages of viral transcription have been altered because of the ATI. Although cellular multiply spliced and unspliced HIV RNA increased during ATI, it was of interest to note that no rise in transcriptionally active cells remained with sustained suppression after ART. We interpret the latter to indicate no long-term impact of a monitored short ATI on host or viral factors in circulation after ART-mediated plasma HIV RNA re-suppression. Future studies will need to assess if tissue level of infected cells is equally unchanged after ART re-suppression following a short-term ATI as suggested by our data.
In addition, our data further support the hypothesis that residual activation on ART is not irreversibly impacted by ATI as evidenced by a return in the frequency of activated T cells to pre-ATI levels after resumption of ART [37] , as well as the lack of difference on T-cell activation baseline levels between patients with or without a history of multiple ATIs (i.e. repeated interruptions arm vs. continuous therapy/single interruption arm). Our data though, do not address cases in which T-cell activation may be increased by causes independent of viral rebound during or after an ATI (i.e. onset of comorbidity). Of interest, although unadjusted analysis did detect a positive association between pre-ATI levels of T-cell activation markers and cellular HIV levels during ATI, no association was observed between T-cell activation on ART and the magnitude of the ATI viral rebound. This finding further supports the interpretation that plasma HIV RNA is a more direct indicator of the 'magnitude of ATI viral rebound' than cellular HIV levels.
This study has limitations. First, cellular HIV DNA and RNA levels were assessed in total PBMC and results were expressed per 10 6 PBMC or per 10 6 CD4 þ T cells based on flow cytometric assessment of % CD4 þ T cells.
Although determinations on isolated CD4
þ T cells would have provided greater sensitivity by removing the potential impact of cellular shifts in PBMC from affecting comparisons between time-points, we did observe a rise in cellular viral measures at a time of decreasing CD4 þ Tcell count (ATI) to support our ability to measure rises within CD4
þ T-cell subsets in PBMC. Second, no direct measurement of integrated DNA was performed. This measurement could further inform whether the observed changes in total DNA and 2-LTR circles observed during this study are not because of changes in the linear or circular unintegrated DNA that is more transient than genomic DNA. Yet no change in the 2-LTR circles was found in our study as a result of the ATI. Furthermore, although not exactly reflecting the amount of integrated DNA, subtraction of 2-LTR from total DNA showed similar results as total DNA suggesting that the observed changes are because of changes in integrated DNA. Future studies assessing changes in integrated DNA could further clarify this. Third, cellular HIV content was assessed by PCR-based assays only; no direct measurement of replication-competent virus or viral sequence diversity was performed. Although recent data suggest that levels of replication-competent virus on ART remain unchanged after ART re-initiation following an ATI as suggested by our data [37] , this needs to be validated in a larger cohort.
Irrespective of viral rebound or immune activation status, all patients undergoing an ATI re-suppressed after restarting ART. It is of interest to note that drug resistance data for 14 of 23 patients participating in this study were previously reported [23, 38] to document a lack of drug resistance emergence predicting failure to re-suppress after resumption of ART. Joining our data with others [33, 36, 37] , clinical evidence to date shows a lack of viral and host adverse effects (resistance, increases in persistent activation/viral levels) following completion of monitored ATIs. As future clinical study designs move forward to test additional cure-directed concepts, the information reported here is expected to further support that the inclusion of monitored ATIs is scientifically warranted.
